Related Experiment Video
Updated: May 26, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Psychotropic drug treatment, clinical characteristics and cognitive processing speed in patients with schizophrenia:
1Department of Psychiatry II, Ulm University, Bezirkskrankenhaus Günzburg, Germany. karel.frasch@bkh-guenzburg.de
Introduction:
Psychotropic drug combinations (PDC) are common in the treatment of patients with schizophrenia but there is little research regarding the effects of PDC on cognition.
Objective:
The aim of this study was to analyse the effects of antipsychotic monotherapy and various types of PDC on cognitive processing speed (CPS).
Methods:
ELAN is a 24-month multi-site prospective observational controlled trial following up 374 patients with schizophrenia under routine treatment conditions following discharge from inpatient treatment. The propensity score method, multinomial logistic regression analyses and mixed effects regression models were used.
Results:
CPS correlated significantly with PANSS and GAF scores and improved over time in the monotherapy group. Negative effects of some PDC (antipsychotics + tranquilizers/antipsychotics+at least 2 other psychopharmacological subclasses, sedative/anticholinergic drugs/high adjusted antipsychotic dose) lost significance after controlling for clinical characteristics.
Discussion:
Indications for PDC should be examined with care although, in the present study, effects on cognition were small.
More Related Videos
12:00Investigating the Effects of Antipsychotics and Schizotypy on the N400 Using Event-Related Potentials and Semantic Categorization
Published on: November 19, 2014
05:14Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Therapy
Antianxiety Medications
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Antipsychotic Drugs: Typical and Atypical Agents
Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...